Viewing Study NCT04164069


Ignite Creation Date: 2025-12-24 @ 11:08 PM
Ignite Modification Date: 2026-01-04 @ 2:53 AM
Study NCT ID: NCT04164069
Status: COMPLETED
Last Update Posted: 2024-12-27
First Post: 2019-10-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Sponsor: Anne Noonan
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module